Some new information on the use of the urine metabolite 11-dehydro thromboxane B2 (UDHT) is emerging from the CHARISMA trial involving 3200 subjects. Dr. John Eikelboom, McMaster University discussed UDHT as a predictor of cardiovascular risk at the European Society of Cardiology meeting September 1, 2008, and provided indications for reducing risk. The abstract is published at Eikelboom J, Hankey GJ, Bhatt DL et al. Incomplete inhibition of thromboxane biosynthesis by ASA: determinants and effect on cardiovascular risk. Abstract. Eur Heart J 2008; 29: 404. I’ve excerpted the project summary below.
In aspirin-treated patients, urinary concentrations of 11-dehydro thromboxane B2 are an externally valid and potentially modifiable determinant of stroke, MI or CV death in patients at risk of atherothrombotic events. The potential for higher doses of ASA and statins to reduce urinary 11-dehydro thromboxane concentrations and CV risk should prompt randomized evaluation of the clinical efficacy of titrating doses according to urinary 11-dehydro thromboxane B2 concentrations, and the clinical efficacy of other treatments that reduce thromboxane production.
No comments here.